Wedbush Reiterates Outperform on Damora Therapeutics, Maintains $40 Price Target

Wedbush analyst David Nierengarten has reiterated an 'Outperform' rating on Damora Therapeutics (NASDAQ: DMRA) and has maintained a price target of $40 for the stock.